Abstract
Purpose
Epirubicin is an antitumor drug, particularly used in the treatment of the breast cancer. The peripheral intravenous infusion of epirubicin frequently causes venous irritation such as, erythema, injection site pain, and phlebitis. The purpose of the present study was to investigate the risk factor associated with the epirubicin-induced venous irritation and to establish a suitable administration method of epirubicin.
Methods
The phlebitis scores (Visual Infusion Phlebitis score) were evaluated retrospectively using the collected nursing record. We analyzed the risk factor associated with venous irritation in 97 patients administered with epirubicin from December 2004 to September 2008. We subsequently changed the regimen of epirubicin and examined the incidence of venous irritation in 26 patients administered with epirubicin from August 2009 to March 2010.
Results
The phlebitis scores were significantly higher in the patients treated with ready-to-use solution compared with lyophilized powder (P = 0.04). Based on this result, we switched the formulation of epirubicin to lyophilized powder. After the intervention, the phlebitis scores were significantly decreased (P = 0.003). An ordinal logistic regression analysis revealed that use of ready-to-use solution was a significant predictor for venous irritation (odds ratio = 3.70; 95%, confidence intervals, 1.29–11.45; P = 0.02).
Conclusions
The use of ready-to-use solution was a risk factor for epirubicin-induced venous irritation. The change of formulation by pharmacist intervention decreased the risk of venous irritation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Glück S (2005) Adjuvant chemotherapy for early breast cancer: optimal use of epirubicin. Oncologist 10:780–791
Cersosimo RJ, Hong WK (1986) Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. J Clin Oncol 4:425–439
Suga Y, Kumazaki M, Nishigami J et al (2009) Improvement of epirubicin-induced phlebitis to switch from liquid preparation to lyophilized formulation. Gan To Kagaku Ryoho 36:93–96
Jackson A (1998) Infection control–a battle in vein: infusion phlebitis. Nurs Times 94:68–71
Kuwahara T, Asanami S, Kawauchi Y et al (1999) Experimental infusion phlebitis: tolerance pH of peripheral vein. J Toxicol Sci 24:113–121
Anami S, Masuda N, Nishikata M et al (2006) Factors associated with phlebitis and venous pain due to intravenous injection of epirubicin hydrochloride. Jpn J Pharm Health Care Sci 32:1105–1110
Sugimoto M, Matsui M, Harada M et al (2009) Prevention of venous pain and phlebitis caused by epirubicin hydrochloride. Gan To Kagaku Ryoho 36:969–974
Polovich M, White JM, Kelleher LO (2005) Chemotherapy and Biotherapy Guideline and Recommendation for Practice. 2nd edn. Pittsburgh, PA
Verso M, Agnelli G (2003) Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 21:3665–3675
Beckers MM, Ruven HJ, Seldenrijk CA et al (2010) Risk of thrombosis and infections of central venous catheters and totally implanted access ports in patients treated for cancer. Thromb Res 125:318–321
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nagata, K., Egashira, N., Yamada, T. et al. Change of formulation decreases venous irritation in breast cancer patients receiving epirubicin. Support Care Cancer 20, 951–955 (2012). https://doi.org/10.1007/s00520-011-1166-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-011-1166-0